R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Net Treatment Benefit in rare disease trials: Aligning trial...

Net Treatment Benefit provides a formal framework to integrate multiple prioritised outcomes into a single measure of overall treatment effect.

R&D

How innovative trial approaches are advancing rare disease r...

Innovative trial designs that harness data augmentation, RWD, and the power of AI are enabling a new era of rare disease research.

R&D

Agentic AI and the human element: Building trustworthy autom...

The future of clinical trials isn’t about replacing people. It’s about empowering them with smarter tools.

R&D

Hexagonal rendering of AI concept on dark blue background

Results, reality, and recalibration: Unpacking AI hype at SC...

SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.

R&D

Why the government’s latest funding push is critical to the ...

Many of the UK’s most promising life sciences innovations continue to face persistent funding challenges, made worse by an increasingly volatile globa

R&D

Navigating development in a complex molecule world

For decades, the pharmaceutical industry has relied on accelerated development and manufacturing timelines to bring new therapies to patients quickly.